Cancer of the ovary, fallopian tube, and peritoneum

Research output: Contribution to journalArticle

Authors

  • Jonathan S Berek
  • Sean Kehoe
  • Lalit Kumar
  • Michael Friedlander

Colleges, School and Institutes

External organisations

  • Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
  • St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.

Abstract

The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.

Bibliographic note

Special Issue: FIGO Cancer Report 2018

Details

Original languageEnglish
Pages (from-to)59-78
Number of pages20
JournalInternational Journal of Gynecology & Obstetrics
Volume143
Issue number52
Publication statusPublished - 11 Oct 2018

Keywords

  • cancer statging, chemotherapy, fallopian tube, FIGO cancer reoprt, ovarian ovary, peritoneum